Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077077 · ClinicalTrials.gov registry record · Phase 1
DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00077077 is a Phase 1 study that has completed, run by Daiichi Sankyo.
The verdict
NCT00077077, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as DJ-927 and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of DJ-927 and capecitabine in treating patients with locally advanced or metastatic solid tumors.
Interventions
- DRUG capecitabine
- DRUG DJ-927
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-02 |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077077
The ClinicalTrials.gov registry entry for NCT00077077 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which capecitabine is the first listed.
NCT00077077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077077 about?
NCT00077077 is a clinical study titled "DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as DJ-927 and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of DJ-927 and cape...
What is the current status of trial NCT00077077?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-02. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00077077?
The interventions under investigation include: capecitabine (DRUG), DJ-927 (DRUG).
Who is sponsoring clinical trial NCT00077077?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.